ProCE Banner Events

Share

Alpha-1 Antitrypsin Deficiency: Are You Overlooking a Leading Genetic Culprit in Liver Disease?

Alpha-1 antitrypsin deficiency associated liver disease (AATD-LD) is a leading genetic cause of liver disease, yet it remains largely underdiagnosed and poorly understood. This encore webinar from a live symposium will feature a multispecialty panel of experts who will provide insights into the pathophysiologic and genetic underpinnings of AATD-LD, best practices in diagnosis, guidance for navigating management, and emerging therapies with the potential to improve patient outcomes.

Physicians: maximum of 1.00 AMA PRA Category 1 Credit™

European Learners: 1.00 EBAC® CE Credit

Who Should Attend

This program is intended for a primary target audience of hepatologists, gastroenterologists, and pulmonologists, as well as a secondary audience of primary care providers, nurse practitioners, physician associates, and pediatricians who manage patients with AATD.

Time and location

Tuesday, January 14, 2025

6:00 PM - 7:00 PM Eastern Time (ET)

Virtual

Faculty
Mark Brantly, MD

Professor Emeritus
Department of Medicine
University of Florida College of Medicine
Gainesville, Florida

Virginia Clark, MD, MS

Clinical Professor of Medicine
Division of Gastroenterology, Hepatology, & Nutrition
University of Florida College of Medicine
Gainesville, Florida

Pavel Strnad, MD

Full Professor
Department of Internal Medicine III
University Hospital Aachen
Aachen, Germany

Jeffrey Teckman, MD

Drs Patrician and James Endowed Chair
Professor of Pediatrics and Biochemistry and Molecular Biology
Vice Chair of Pediatrics
St Louis University School of Medicine
Cardinal Glennon Children’s Hospital
St Louis, Missouri

Agenda

  • Overview of Alpha-1 Antitrypsin Deficiency Liver Disease
  • Best Practices in Diagnosis and Assessment
  • Navigating Current Management Strategies
  • Emerging Targeted Therapeutic Strategies

CME/CE Info

Goal Statement
The goal of this activity is to improve the knowledge and competence of HCPs in diagnosing and assessing AATD-LD and provide them with practical strategies for optimizing disease management.

Target Audience
This program is intended for a primary target audience of hepatologists, gastroenterologists, and pulmonologists, as well as a secondary audience of primary care providers, nurse practitioners, physician associates, and pediatricians who manage patients with AATD.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Identify clinical manifestations of AATD-LD

  • Position recommended diagnostic procedures for suspected AATD-LD

  • Implement noninvasive tests to assess liver fibrosis in patients with AATD-LD 

  • Summarize investigational therapeutic approaches for AATD-LD 

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME Passport

662be69741e7b.png

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit www.cmepassport.org to create your account.

EBAC® Accreditation

https://omni-channel-2022-assets-production.s3.amazonaws.com/editorupload/670013d9e7266.jfif

This program is accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC®) for 1.0 hour of effective education time.

EBAC® holds an agreement on mutual recognition of substantive equivalency with the US Accreditation Council for CME (ACCME) and the Royal College of Physicians and Surgeons of Canada, respectively.

Through an agreement between the European Board for Accreditation of Continuing Education for Health Professionals and the American Medical Association, physicians may convert EBAC® CE credits/points to AMA PRA Category 1 Credits™. Information on the process to convert EBAC® credit to AMA credit can be found on the AMA website. Other health care professionals may obtain from the AMA a certificate of having participated in an activity eligible for conversion of credit to AMA PRA Category 1 Credit™.

EBAC® is a member of the International Academy for CPD Accreditation (IACPDA) and a partner member of the International Association of Medical Regulatory Authorities (IAMRA).

Acknowledgement

Provided by Clinical Care Options, LLC

Supported by an educational grant from Takeda Development Center Americas, Inc.

Contact Information

For customer support please click here.

Mailing Address:

 

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Additional Information

There are no fees required to participate in this activity.

Americans With Disabilities Act
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact Customer Support prior to the live event.